Steroid resistant nephrotic syndrome in children: Clinical presentation, renal histology, complications, treatment and outcome at Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

R. Roy, Haque Sms, Mamun Aa, Golam Muinuddin, Md. Habibur Rahman
{"title":"Steroid resistant nephrotic syndrome in children: Clinical presentation, renal histology, complications, treatment and outcome at Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh","authors":"R. Roy, Haque Sms, Mamun Aa, Golam Muinuddin, Md. Habibur Rahman","doi":"10.9790/3013-040110107","DOIUrl":null,"url":null,"abstract":"Steroid resistant nephrotic syndrome (SRNS) remains a challenge for pediatric nephrologists. The underlying histopathology usually affects the course of the disease and the response to treatment. This study was designed to determine clinical presentation, renal histology, complications, treatment and outcome in children presenting with SRNS. A prospective analysis was carried out among 32 steroid resistant nephrotic syndrome patients aged 1-18 year in the department of pediatric nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh during the period of January 2011 to June 2014. Percutaneous renal biopsy were done in all patients. The histopathology slides were reviewed by competent pathologists. Patients with congenital nephrotic syndrome and nephrotic syndrome secondary to systemic diseases were excluded from the study. Thirty two children fulfilled the inclusion criteria, and included 19 boys and 13 girls, male to female ratio was 1.4:1. Their mean age of presentation was 9.2 year (range 16 month to 16 year). Nine patient(28.22) presented with typical presentation and 23 (71.88%) presented with atypical presentation which included hematuria (62.5%), very high cholesterol (>500mg/dl), persistent hypertension (40.63%), unfavorable age (28.13%), hypocomplementemia (21.88%) and azotemia. None had a positive family history or hepatitis B surface antigen. The renal histopathology was compatible with mesengioproliferative glomerulonephritis (MesPGN) in 40.63%% (n=17), membranoproliferative glomerulonephritis (MPGN) 21.88% (n=07), minimal change disease (MCD) 18.75% (n=06), focal and segmental glomerulosclerosis (FSGS) in 12.5% (n=4) and inadequate tissue was found in two cases. All patients were treated by intravenous methylprednisolone four to six pulses along with intravenous cyclophosphamide followed by oral prednisolone. Cyclosporine was added in patients who failed to achieve remission The outcome with steroid and cyclophosphamide-based treatment for iSRNS was further enhanced with addition of ACE inhibitor. Regarding outcome 21(65.63%) patient responded, five (15.63%) patients died, four (12.5%) reached end stage renal disease and two refused to take any treatment. This study revealed that MesPGN was the commonest histopathology in children presented with SRNS, IV methylprednisolone and IV cyclophosphamide are still agood option for treatment of SRNS with a response rate of sixty five percent. KEY WORD: Management, Nephrotic syndrome, Outcome","PeriodicalId":14540,"journal":{"name":"IOSR Journal of Pharmacy","volume":"25 1","pages":"01-07"},"PeriodicalIF":0.0000,"publicationDate":"2014-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IOSR Journal of Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9790/3013-040110107","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Steroid resistant nephrotic syndrome (SRNS) remains a challenge for pediatric nephrologists. The underlying histopathology usually affects the course of the disease and the response to treatment. This study was designed to determine clinical presentation, renal histology, complications, treatment and outcome in children presenting with SRNS. A prospective analysis was carried out among 32 steroid resistant nephrotic syndrome patients aged 1-18 year in the department of pediatric nephrology, Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh during the period of January 2011 to June 2014. Percutaneous renal biopsy were done in all patients. The histopathology slides were reviewed by competent pathologists. Patients with congenital nephrotic syndrome and nephrotic syndrome secondary to systemic diseases were excluded from the study. Thirty two children fulfilled the inclusion criteria, and included 19 boys and 13 girls, male to female ratio was 1.4:1. Their mean age of presentation was 9.2 year (range 16 month to 16 year). Nine patient(28.22) presented with typical presentation and 23 (71.88%) presented with atypical presentation which included hematuria (62.5%), very high cholesterol (>500mg/dl), persistent hypertension (40.63%), unfavorable age (28.13%), hypocomplementemia (21.88%) and azotemia. None had a positive family history or hepatitis B surface antigen. The renal histopathology was compatible with mesengioproliferative glomerulonephritis (MesPGN) in 40.63%% (n=17), membranoproliferative glomerulonephritis (MPGN) 21.88% (n=07), minimal change disease (MCD) 18.75% (n=06), focal and segmental glomerulosclerosis (FSGS) in 12.5% (n=4) and inadequate tissue was found in two cases. All patients were treated by intravenous methylprednisolone four to six pulses along with intravenous cyclophosphamide followed by oral prednisolone. Cyclosporine was added in patients who failed to achieve remission The outcome with steroid and cyclophosphamide-based treatment for iSRNS was further enhanced with addition of ACE inhibitor. Regarding outcome 21(65.63%) patient responded, five (15.63%) patients died, four (12.5%) reached end stage renal disease and two refused to take any treatment. This study revealed that MesPGN was the commonest histopathology in children presented with SRNS, IV methylprednisolone and IV cyclophosphamide are still agood option for treatment of SRNS with a response rate of sixty five percent. KEY WORD: Management, Nephrotic syndrome, Outcome
儿童类固醇抵抗性肾病综合征:临床表现、肾脏组织学、并发症、治疗和结果在孟加拉国达卡的Bangabandhu Sheikh Mujib医科大学
类固醇抵抗性肾病综合征(SRNS)仍然是儿科肾病学家面临的挑战。潜在的组织病理学通常影响疾病的进程和对治疗的反应。本研究旨在确定SRNS患儿的临床表现、肾脏组织学、并发症、治疗和预后。前瞻性分析了2011年1月至2014年6月期间在孟加拉国达卡Bangabandhu Sheikh Mujib医科大学儿科肾病科收治的32例1-18岁的类固醇抵抗性肾病综合征患者。所有患者均行经皮肾活检。组织病理切片由有能力的病理学家检查。先天性肾病综合征和继发于全身性疾病的肾病综合征患者被排除在研究之外。符合纳入标准的患儿32例,其中男19例,女13例,男女比例为1.4:1。他们的平均发病年龄为9.2岁(16个月至16岁)。典型临床表现9例(28.22),不典型临床表现23例(71.88%),不典型临床表现包括血尿(62.5%)、高胆固醇(500mg/dl)、持续性高血压(40.63%)、年龄不利(28.13%)、低补体血症(21.88%)和氮质血症。没有人有阳性家族史或乙型肝炎表面抗原。肾组织病理学表现为:间膜增生性肾小球肾炎(MesPGN)占40.63% (n=17),膜增生性肾小球肾炎(MPGN)占21.88% (n=07),微小病变(MCD)占18.75% (n=06),局灶性和节段性肾小球硬化(FSGS)占12.5% (n=4), 2例组织不足。所有患者均静脉注射甲基强的松龙4至6次脉冲,同时静脉注射环磷酰胺,然后口服强的松龙。在未能达到缓解的患者中加入环孢素,类固醇和环磷酰胺为基础的iSRNS治疗的结果随着ACE抑制剂的加入而进一步增强。结果21例(65.63%)患者应答,5例(15.63%)患者死亡,4例(12.5%)患者达到终末期肾病,2例拒绝接受任何治疗。本研究显示,MesPGN是SRNS患儿中最常见的组织病理学,静脉注射甲基强的松龙和静脉注射环磷酰胺仍然是治疗SRNS的良好选择,有效率为65%。关键词:管理,肾病综合征,结局
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信